SCHEMBL25957834

SCHEMBL25957834

CC(=O)COCC(F)CN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.41
▸ POLB P06746 3/20 0.40
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CRHBP P24387 1/20 0.38
▸ CRHR2 Q13324 1/20 0.38
▸ CA12 O43570 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ LMNA P02545 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21070657 0.88 ALDH1A1 (0.40) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL21070020 0.84 ALDH1A1 (0.45) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL21069389 0.82 ALDH1A1 (0.36) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL21070134 0.82 ALDH1A1 (0.36) ALDH1A1POLBNPC1RAB9ASMN1; SMN2
SCHEMBL21069499 0.81 IRAK4 (0.38) ALDH1A1POLBNPC1RAB9AMEN1
SCHEMBL21070795 0.81 IRAK4 (0.38) ALDH1A1POLBNPC1RAB9AMEN1
SCHEMBL21070298 0.79 ALDH1A1 (0.40) ALDH1A1POLBNPC1MEN1KMT2A
SCHEMBL25957832 0.79 POLB (0.45) ALDH1A1POLBNPC1L3MBTL1CYP1A2
SCHEMBL21328902 0.79 POLB (0.42) ALDH1A1POLBNPC1LMNANPSR1
SCHEMBL15688749 0.79 POLB (0.42) ALDH1A1POLBNPC1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885POLB 2088/4885NPC1 3159/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885POLB 2088/4885NPC1 3159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback